Communicable Diseases: Clinical Trials

2,089 trials for Communicable Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1511 completed, 189 terminated, 141 unknown, 78 recruiting. 2089 Phase 2, 329 Phase 1, 160 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22089Completed 1511, Terminated 189, Unknown 141, Recruiting 78, Withdrawn 78, Active not recruiting 43, Not yet recruiting 41, Suspended 7, Enrolling by invitation 1
Phase 1329Completed 223, Terminated 30, Unknown 23, Recruiting 17, Withdrawn 14, Not yet recruiting 12, Active not recruiting 10
Phase 3160Completed 102, Terminated 19, Unknown 15, Withdrawn 11, Recruiting 5, Active not recruiting 4, Not yet recruiting 3, Suspended 1

Follow Communicable Diseases: new trials by email Literature Review of Communicable Diseases trials Research Report on Communicable Diseases

Trials (filtered) newest first · largest first

All 2,089 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Topical Curcumin for HPV Related Cervical Disease
Curcumin C3 Complex, Placebo - Neoplasm Cervix
Phase 2Not yet recruitingLisa Flowers2002027-04-012026-05-08
Reducing Arterial Inflammation Using Eplerenone and Statins in HIV
Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD)
Phase 2 / Phase 3Not yet recruitingMassachusetts General Hospital1242027-03-012026-10-23
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
ATRN-119, Stereotactic Body Radiation Therapy (SBRT) - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma
Phase 1 / Phase 2Not yet recruitingAbramson Cancer Center at Penn Medicine352027-01-312026-10-27
Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa
VPM1002 Vaccine, BCG Vaccine, Placebo - Tuberculosis, HIV Infections
Phase 1 / Phase 2WithdrawnInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group2026-12-312026-08-17
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
DOR/ISL - HIV-1, HIV Infection
Phase 2Not yet recruitingMerck Sharp & Dohme LLC452026-12-232026-10-07
Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy
- Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml - HIV - Human Immunodeficiency Virus
Phase 2Not yet recruitingANRS, Emerging Infectious Diseases362026-12-012026-10-01
A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients
Entecavell ODT - Hepatitis B Virus, Liver Transplant
Phase 2Not yet recruitingJongman Kim822026-12-012026-10-28
Psilocybin Therapy for Methamphetamine Use Disorder and HIV
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Phase 2RecruitingNicky Mehtani, MD, MPH302026-12-012026-11-09
Baricitinib Curative Repression of HIV-1
Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg - HIV Infection, HIV
Phase 2Not yet recruitingEmory University352026-12-012026-11-13
A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size
Ixazomib 4 mg, Placebo - HIV (Human Immunodeficiency Virus)
Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)452026-11-232026-11-12
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
PRGN-2012, Bevacizumab - Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Phase 2Not yet recruitingNational Cancer Institute (NCI)502026-11-182026-11-13
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
10vHPV, Gardasil9 - Human Papillomavirus Infection
Phase 1 / Phase 2Not yet recruitingSerum Institute of India Pvt. Ltd.722026-11-012026-11-06
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
AHB-137, Placebo, TVAX-008 - Chronic Hepatitis B
Phase 1 / Phase 2Not yet recruitingAusper Biopharma Co., Ltd.1052026-10-312026-10-19
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
AHB-137, TVAX-008, Placebo - Chronic Hepatitis B
Phase 1 / Phase 2Not yet recruitingGrand Theravac Life Sciences (Hangzhou) Co., Ltd.1052026-10-312026-10-27
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
Isoniazid, Rifampin, Pyrazinamide - Tuberculosis
Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)9002026-10-302026-08-19
A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB)
HT-101 + HT-102, HT-101 placebo + HT-102 placebo - Chronic Hepatitis B Virus Infection
Phase 2Not yet recruitingSuzhou HepaThera Biotech Co., Ltd.1202026-10-302026-11-05
Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues
YKYY013, YKYY013 Placebo - HBV (Hepatitis B Virus)
Phase 2Not yet recruitingBeijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.1202026-10-302026-11-12
A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)
VH4011499, CAB, DTG/3TC - HIV Infections
Phase 2Not yet recruitingViiV Healthcare2002026-10-192026-09-11
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer
Phase 2RecruitingUniversity of Maryland, Baltimore1322026-10-192026-11-06
Treatment of CKD Patients With HCV
SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients
Phase 2 / Phase 3Not yet recruitingTanta University502026-09-152026-08-20

Showing 20 of 2089. Sign in to see all of them.

Narrower conditions

HIV Infections (919)  ·  Acquired Immunodeficiency Syndrome (418)  ·  Hepatitis C (339)  ·  Hepatitis C, Chronic (227)  ·  Hepatitis B, Chronic (188)  ·  Hepatitis B (163)  ·  Papillomavirus Infections (91)  ·  AIDS-Related Complex (56)  ·  Infections (51)  ·  Sexually Transmitted Diseases (47)  ·  Hepatitis (46)  ·  Tuberculosis (33)  ·  Virus Diseases (32)  ·  Liver Diseases (27)

Broader conditions

Infections (2038)  ·  Virus Diseases (1988)  ·  Blood-Borne Infections (1881)  ·  RNA Virus Infections (1630)  ·  Urogenital Diseases (1304)  ·  Genital Diseases (1298)  ·  Sexually Transmitted Diseases, Viral (1258)  ·  Sexually Transmitted Diseases (1250)  ·  Immune System Diseases (1163)  ·  Lentivirus Infections (1145)  ·  Retroviridae Infections (1145)  ·  Immunologic Deficiency Syndromes (1142)  ·  Digestive System Diseases (797)  ·  Hepatitis, Viral, Human (771)

Interventions

Ribavirin (229)  ·  peginterferon alfa-2a (133)  ·  Ritonavir (106)  ·  Tenofovir (94)  ·  Zidovudine (80)  ·  Lamivudine (72)  ·  Sofosbuvir (53)  ·  entecavir (53)  ·  Didanosine (49)  ·  efavirenz (46)  ·  Stavudine (45)  ·  Emtricitabine (44)  ·  peginterferon alfa-2b (37)  ·  Lopinavir (35)  ·  Indinavir (32)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (297)  ·  Gilead Sciences (90)  ·  Merck Sharp & Dohme LLC (73)  ·  GlaxoSmithKline (61)  ·  Bristol-Myers Squibb (43)  ·  ViiV Healthcare (41)  ·  Hoffmann-La Roche (32)  ·  French National Agency for Research on AIDS and Viral Hepatitis (30)  ·  National Cancer Institute (NCI) (30)  ·  ANRS, Emerging Infectious Diseases (29)  ·  Boehringer Ingelheim (24)  ·  Centers for Disease Control and Prevention (21)  ·  Tibotec Pharmaceuticals, Ireland (19)  ·  National Center for Complementary and Integrative Health (NCCIH) (17)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (17)

Countries

United States (1077)  ·  France (185)  ·  Puerto Rico (180)  ·  Canada (173)  ·  Germany (152)  ·  China (140)  ·  Spain (131)  ·  United Kingdom (125)  ·  South Africa (123)  ·  Italy (91)  ·  Thailand (91)  ·  Australia (88)  ·  Belgium (71)  ·  New Zealand (67)  ·  South Korea (65)

Top investigators

Kiat Ruxrungtham, MD (7)  ·  Marc G Ghany, M.D. (7)

Results publications

PMID 40190112, PMID 41276263, PMID 34895272, PMID 25424918, PMID 28193518, PMID 30012435, PMID 30923816, PMID 30977945, PMID 34817414, PMID 40342086, PMID 40655875, PMID 18832244, PMID 18832245, PMID 19118378, PMID 19191652, PMID 20091678, PMID 20657177, PMID 20672447, PMID 20703158, PMID 22336878, PMID 24154738, PMID 24209977, PMID 24391139, PMID 24419064, PMID 24983020, PMID 25164700, PMID 25296098, PMID 25445400, PMID 25820067, PMID 25830171, PMID 26596948, PMID 26683763, PMID 26691547, PMID 26752189, PMID 26902761, PMID 27257978, PMID 27566633, PMID 28340322, PMID 28412293, PMID 28802814, PMID 28802816, PMID 30850240, PMID 31042791, PMID 31108015, PMID 31179503, PMID 31464859, PMID 31568620, PMID 31824943, PMID 32827835, PMID 33493795

NIH funding

2014 (22), 2009 (16), 2015 (16), 2016 (14), 2008 (12), 2019 (11), 2023 (8), 2004 (7), U01CA121947 (6), UM1CA121947 (6), 2017 (5), 2018 (5), U01AI068636 (5), 2005 (4), 2025 (4)